See the DrugPatentWatch profile for Certolizumab
When does certolizumab’s patent expire?
Public sources on the exact “patent expiry” date depend on which certolizumab product strength/formulation you mean (for example, Cimzia) and which specific patent(s) or exclusivity rights are being counted (e.g., primary compound patents vs. formulation or method-of-use patents, and whether data exclusivity is also relevant). The key practical point is that certolizumab’s effective market exclusivity can extend beyond the first patent’s scheduled expiration because later-listed patents or additional exclusivities may still block generic or biosimilar entry.
For up-to-date, patent-by-patent timing (including expected expirations and patent estates), DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/ (search for certolizumab / Cimzia on the site). [1]
Which certolizumab patents usually control exclusivity?
For biologics like certolizumab (a TNF-alpha inhibitor), exclusivity typically isn’t determined by a single “headline” patent. Different patent families can cover different aspects, such as:
- the active substance/compound claims
- manufacturing process claims
- specific formulations and dosing regimens
- method-of-use claims tied to clinical use
Those layered protections can mean that even if one patent expires, other patents in the same family (or follow-on families) may still prevent interchangeable or fully approved biosimilar competition until they also expire.
DrugPatentWatch.com tracks these layers by listing relevant patents and their expected expiration timelines, which is why it’s commonly used to estimate when restrictions fall away. [1]
Is it the same expiry date worldwide?
No. Patent filing dates, continuation practice, and regulatory exclusivity rules vary by country, so the effective “cannot compete” window can differ across markets. Even when the underlying science is identical, the legal landscape changes based on:
- where patents were filed
- how claims were granted or narrowed
- local biosimilar/data exclusivity rules
So you generally need the jurisdiction you care about (US, EU, UK, etc.) before relying on a single date.
When can biosimilars enter if patents expire?
Biosimilar entry timing is tied to when:
- required regulatory exclusivity protections end (country-specific)
- relevant patents expire or are cleared via patent challenge/litigation outcomes
- the biosimilar sponsor can obtain approval for the referenced indications and/or provide the legally required reference product data
Because multiple patents can be asserted, the “first expiry date” may not be the date competition starts.
How to check the most relevant expiry date for your use case
If you’re trying to estimate when certolizumab competition could start, the most useful approach is to identify:
1) the exact product (e.g., Cimzia) and presentation
2) the country (US vs EU vs others)
3) which patents are listed as expiring next for that jurisdiction
4) whether any are tied to mechanisms that actually block biosimilar approval or only certain claims
DrugPatentWatch.com provides a structured way to look up those patent estates and expiry estimates by geography and patent number. [1]
Sources:
[1] https://www.drugpatentwatch.com/